Review
Oncology
Ya-Juan Zhu, Xiong Li, Ting-Ting Chen, Jia-Xiang Wang, Yi-Xin Zhou, Xiao-Li Mu, Yang Du, Jia-Ling Wang, Jie Tang, Ji-Yan Liu
Summary: Neoantigens, as cancer-specific aberrant peptides, can trigger robust immune response and hold great promise as an effective treatment approach for patients with CRC.
CLINICAL AND TRANSLATIONAL MEDICINE
(2023)
Review
Immunology
Hang Yin Chu, Zihao Chen, Luyao Wang, Zong-Kang Zhang, Xinhuan Tan, Shuangshuang Liu, Bao-Ting Zhang, Aiping Lu, Yuanyuan Yu, Ge Zhang
Summary: Wnt antagonist Dickkopf-1 (DKK1) is highly expressed in multiple cancers and associated with poor prognosis, promoting cancer growth and influencing immune cell activities, particularly MDSCs and CD8(+) T cells. DKK1 is considered a promising target for cancer immunotherapy, with ongoing research aimed at elucidating its functional mechanisms.
FRONTIERS IN IMMUNOLOGY
(2021)
Review
Oncology
Lin-Lin Sun, Dong-Li Linghu, Mien-Chie Hung
Summary: Ferroptosis, a newly recognized type of programmed cell death, plays an important role in cancer biology and therapies. Certain tumors, such as TNBC, are particularly vulnerable to ferroptosis inducers. Recent studies suggest that ferroptosis is involved in T cell-mediated anti-tumor immunity.
AMERICAN JOURNAL OF CANCER RESEARCH
(2021)
Article
Immunology
Jiawei Shou, Fan Mo, Shanshan Zhang, Lantian Lu, Ning Han, Liang Liu, Min Qiu, Hongseng Li, Weidong Han, Dongying Ma, Xiaojie Guo, Qianpeng Guo, Qinxue Huang, Xiaomeng Zhang, Shengli Ye, Hongming Pan, Shuqing Chen, Yong Fang
Summary: This study investigated the synergistic effects of radiofrequency ablation (RFA) and personalized neoantigen-based peptide vaccine in cancer patients and mouse models. The results showed improved clinical and immune responses in cancer patients who received neoantigen vaccination after RFA treatment. Mouse models also confirmed the synergistic antitumor effects of RFA and neoantigen vaccines.
FRONTIERS IN IMMUNOLOGY
(2022)
Review
Immunology
Yu Hao, Xinxuan Zhou, Yiling Li, Bolei Li, Lei Cheng
Summary: Cluster of differentiation 47 (CD47) is a transmembrane protein that is widely present on cell surfaces and overexpressed by cancer cells. It interacts with signal-regulatory protein a (SIRPa) to inhibit macrophage-mediated phagocytosis and achieve immune escape. Targeting the CD47-SIRPa axis as a cancer immunotherapy has shown promising results in pre-clinical studies.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2023)
Review
Biochemistry & Molecular Biology
Xiali Qin, Yu Gu, Tianyu Liu, Chen Wang, Weilong Zhong, Bangmao Wang, Hailong Cao
Summary: This review summarizes the current research progress on fungal dysbiosis in CRC, discusses the potential mechanisms of fungi in CRC development, and explores potential therapeutic strategies for CRC treatment. This contributes to a better understanding of the correlation between fungal community and CRC, with modulating fungal community being a promising target against CRC.
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER
(2021)
Review
Medicine, Research & Experimental
Ganjun Yu, Xiaobo He, Xing Li, Yanfeng Wu
Summary: Neoantigens, as tumor-specific antigens, have been recognized as ideal targets for immunotherapy and are utilized in cancer vaccines to elicit specific immune responses for tumor elimination. Despite their promising clinical efficacy, challenges remain to be addressed in the development and application of neoantigen vaccines.
BIOMEDICINE & PHARMACOTHERAPY
(2022)
Review
Oncology
Yuansen Li, Yi Lei, Jiaxue Sun, Wanfu Zhang, Xiaogang Li, Sijing Chen, Deshenyue Kong, Cheng Chen, Ke Bi, Xiao Luo, Hui Wang, Bo Li, Huayou Luo, Yu Xu
Summary: Colorectal cancer is a significant global cause of cancer death, and immunotherapy using CCL5 as a potential target shows promise in improving treatment outcomes for CRC patients.
FRONTIERS IN ONCOLOGY
(2022)
Article
Biochemistry & Molecular Biology
Daichao Wu, Ragul Gowathaman, Brian G. Pierce, Roy A. Mariuzza
Summary: Adoptive cell therapy with tumor-specific T cells can lead to long-term cancer regression. This study focuses on understanding how T cells recognize cancer-specific antigens at the atomic level, particularly the p53R175H mutation. The researchers found that TCR 6-11, unlike other TCRs, recognizes the mutant p53 indirectly, without directly contacting the mutation site. The difference in binding affinity between mutant and wild-type p53 is mainly attributed to the energetic cost of desolvation in the wild-type peptide. This study highlights the diversity of recognition strategies and provides insights into developing T cell therapies with selectivity against tumor cells.
JOURNAL OF BIOLOGICAL CHEMISTRY
(2022)
Review
Oncology
Alyssa Min Jung Kim, Macy Rose Nemeth, Seung-Oe Lim
Summary: Immunotherapy has become an important therapeutic strategy for treating various diseases, including cancer. The 4-1BB receptor has shown promise as a therapeutic target in cancer immunotherapy and has garnered significant attention and research.
FRONTIERS IN ONCOLOGY
(2022)
Review
Pharmacology & Pharmacy
Yaaqub Abiodun Uthman, Kasimu Ghandi Ibrahim, Bilyaminu Abubakar, Muhammad Bashir Bello, Ibrahim Malami, Mustapha Umar Imam, Naeem Qusty, Natalia Cruz-Martins, Gaber El-Saber Batiha, Murtala Bello Abubakar
Summary: In recent years, cancer metastasis research has become a significant topic in the development of anticancer therapies. MALAT1, a non-coding RNA associated with metastatic colorectal cancer, plays a role in tumor cell proliferation, migration, metastasis, and survival.
BIOCHEMICAL PHARMACOLOGY
(2021)
Article
Biochemistry & Molecular Biology
Kaixuan Diao, Jing Chen, Tao Wu, Xuan Wang, Guangshuai Wang, Xiaoqin Sun, Xiangyu Zhao, Chenxu Wu, Jinyu Wang, Huizi Yao, Casimiro Gerarduzzi, Xue-Song Liu
Summary: Seq2Neo is a pipeline that predicts the immunogenicity of neoantigens by providing a solution for neoepitope feature prediction using raw sequencing data. It supports different types of genome DNA alterations and includes a CNN-based model that shows improved performance in immunogenicity prediction compared to currently available tools.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Oncology
Yao-Jun Yu, Na Shan, Li-Yi Li, Yue-Sheng Zhu, Li-Miao Lin, Chen-Chen Mao, Ting-Ting Hu, Xiang-Yang Xue, Xiao-Ping Su, Xian Shen, Zhen-Zhai Cai
Summary: This study aimed to evaluate the efficacy of personalized neoantigen vaccine in treating MSS-CRC patients with recurrence or metastasis after surgery and chemotherapy. Candidate neoantigens were identified from tumor tissues through whole-exome and RNA sequencing. The vaccine showed a specific immune response in 66.67% of vaccinated patients, and four patients remained progression-free up to the completion of the clinical trial. Changes in health-related quality of life improved for almost all patients after the vaccine treatment. These results suggest that personalized neoantigen vaccine therapy is a safe, feasible, and effective strategy for MSS-CRC patients with postoperative recurrence or metastasis.
CANCER IMMUNOLOGY IMMUNOTHERAPY
(2023)
Article
Oncology
Laura Schaekel, Salahuddin Mirza, Riekje Winzer, Vittoria Lopez, Riham Idris, Haneen Al-Hroub, Julie Pelletier, Jean Sevigny, Eva Tolosa, Christa E. Mueller
Summary: The study found that ceritinib, an anti-cancer drug, can also effectively inhibit CD39, providing a basis for the development of more potent CD39 inhibitors.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Review
Immunology
Long Yuan, Jahnavi Tatineni, Kathleen M. Mahoney, Gordon J. Freeman
Summary: VISTA, a B7 family member, plays a role in maintaining immune cell quiescence and is a potential target for cancer immunotherapy. It reprograms macrophages and its interaction with ligands is regulated by pH, suggesting targeting intratumoral pH could enhance antitumor immune responses. Additionally, differences among VISTA therapeutics and their potential as candidate immunotherapies are being actively researched.
TRENDS IN IMMUNOLOGY
(2021)
Article
Biotechnology & Applied Microbiology
Peipei Wang, Yueyun Chen, Yue Zheng, Yang Fu, Zhenyu Ding
Summary: High expression of PLA2G4E-AS1, AC063976.1, and LINC01592 is associated with favorable overall survival in Chinese ESCC patients, and a risk score based on these lncRNAs can stratify patients into low- and high-risk groups.
Article
Oncology
Peipei Wang, Yueyun Chen, Qingqin Long, Qing Li, Jiangfang Tian, Ting Liu, Yong Wu, Zhenyu Ding
Summary: The study found that high expression of PD-L1, TIM3, and TIGIT was associated with poor overall survival in patients with esophageal squamous cell carcinoma. PD-L1/TIM3 and PD-L1/TIGIT were identified as the optimal combinations for predicting survival rates, potentially serving as targets for future ICB therapy for ESCC.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Article
Oncology
Ye Hong, Ping Duan, Lang He, Qing Li, Yueyun Chen, Peipei Wang, Yang Fu, Ting Liu, Zhenyu Ding
Summary: This study aimed to explore the relationship between the systematic immunological level and prognosis of lung cancer patients with leptomeningeal metastases (LM), and to establish a prognostic model for predicting patient survival. The results showed that the systematic immunological level was an independent prognostic factor for these patients.
CANCER MANAGEMENT AND RESEARCH
(2022)
Article
Medicine, General & Internal
Peipei Wang, Yuling Zhang, Qinghua Cai, Qingqin Long, Shiyi Pan, Wei Zhou, Tingfen Deng, Wenjian Mo, Shunqing Wang, Yuping Zhang, Caixia Wang, Cunte Chen
Summary: High expression of CD276, BAG3, and SRC is associated with poor overall survival in AML patients. The co-expression patterns of CD276 and BAG3/SRC could potentially serve as biomarkers for risk stratification and designing combination immuno-targeted therapy in AML.
ANNALS OF MEDICINE
(2023)
Article
Oncology
Peipei Wang, Jianwei Zhu, Qingqin Long, Yan Wang, Huihua Xu, Huimin Tao, Biwen Wu, Jiajun Li, Yong Wu, Sihong Liu
Summary: Our study found that a lncRNA called SATB2-AS1 is up-regulated in osteosarcoma tissue and promotes the proliferation of osteosarcoma cells in vitro. We used transcriptome sequencing data from patients with osteosarcoma to evaluate the importance of SATB2-AS1 and SATB2 on the prognosis. The co-expression of SATB2-AS1 and SATB2 is associated with poor overall survival and relapse-free survival in patients with osteosarcoma.
JOURNAL OF BONE ONCOLOGY
(2023)